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Summary In this preclinical study, the potential applicability of an anti-B7-1 immunotoxin (IT) forthe treatment of Hodgkin's disease (HD) was
investigated. Immunohistochemical analysis demonstrated strong expression of B7-1 on Hodgkin and Reed-Sternberg (R-S) cells and clear
expression on dendritic cells, macrophages and some B-cells in tissues, but not on other tissue cells. Flow cytometric analysis demonstrated
that B7-1 was expressed on a few monocytes, but not on CD34+ cells from bone marrow, resting T- or B-cells from peripheral blood or
epithelial and endothelial cell lines. An anti-B7-1 immunotoxin containing the anti-B7-1 monoclonal antibody (MAb) B7-24 and saporin as toxin
moiety was constructed and showed an affinity similar to that shown by the native MAb. It exhibited strong cytotoxicity againstthe B7-1 + B-cell
line Raji (IC50 10-11 M), R-S cell lines HDLM2, KM/H2 and L428 and also against a B7-1-transfected epithelial cell line, A431, whose parental
line lacks expression of B7-1. In clonogenic assays with Raji cells or KM/H2 cells, a 3- or4-log kill, respectively, was observed. No cytotoxicity
was found against the B7-1- epithelial and endothelial cell lines or against haematopoietic progenitor cells. In conclusion, an anti-B7-1
immunotoxin was developed that had good cytotoxicity against R-S cell lines and that may be used in the elimination of R-S cells in vivo. A
concomitant elimination of activated antigen-presenting cells may avoid development of antitoxin and anti-mouse Ig responses and allow
repeated administration.
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Hodgkin's disease (HD) comprises a group of malignant
lymphomas of mixed cell type that share clinical and pathological
features. Typically, there is the presence of mononucleated
Hodgkin cells and multinucleated Reed-Stemnberg cells (H/R-S)
surrounded by a mixture of activated but non-malignant lympho-
cytes, histiocytes and eosinophils (Poppema, 1989; Haluska et al,
1994). In HD, the constitutional 'B' symptoms such as fever, night
sweats, generalized itching and weight loss, and other clinical
features, such as eosinophilia, acute-phase reactants, thrombo-
cytosis and sclerosis ofHD-involved tissues, are very likely caused
by an unbalanced production ofcytokines by these H/R-S cells.
HD is a tumour that is highly responsive to both chemotherapy
and radiotherapy (DeVita and Molloy Hubbard, 1993). Most
patients with early-stage disease can be cured by single-modality
treatment. Advanced HD is generally treated with combination
chemotherapy with good results. However, about 20% of patients
will eventually sufferfrom a drug-resistant relapse oftheirdisease.
For these patients, and for patients with primary resistant HD,
other treatment strategies are warranted. A promising approach is
immunotherapy using monoclonal antibodies (MAbs) to deliver
therapeutically active agents to the cancer site. As H/R-S cells are
believed to be the malignant cells in HD, these cells seem to be the
best target for such immunotherapy. The antigenic make-up of
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H/R-S cells include several well-expressed surface antigens:
CD15, CD30, CD40, IL-2R (CD25), transferrin receptor (CD71),
B7-1 (CD80) and B7-2 (CD86) (Schwarting et al, 1989; Durkop et
al, 1992; Falini et al, 1992a; Nozawa etal, 1993; Smith et al, 1993;
Gruss et al, 1994; Munro et al, 1994; Falini etal, 1995), to which a
therapeutic agent could be targeted. The active moiety coupled to a
MAb may consist of a radio isotope (radioimmunoconjugate)
(Vriesendorp et al, 1991) or a protein synthesis-inactivating toxin
(immunotoxin, IT) (Falini et al, 1992b). As treatment modality for
HD, immunotoxins may be preferred to radioimmunoconjugates,
as the latter are less well targeted to aparticularcell type, andother
cells around the H/R-S cells will be damaged. Moreover, patients
have often been treated with radiotherapy in an early stage oftheir
disease, which may result in radioresistance. The efficacy ofan IT
depends largely on the choice ofthe target antigen. As ITs display
their toxic action only inside the cell, efficacy ofan IT depends, in
addition to the level of antigen expression, on internalization and
intracellular routing of the IT. Furthermore, not only reactivity of
the MAb to the neoplastic cells should be considered but also reac-
tivity to othercells and tissues, as serious problems may arise from
using broadly reactive MAbs because of destruction of healthy
tissues (Pai et al, 1991).
In this study, we have evaluated whether an anti-B7-1 ITcould be
a possible HD treatment, taking into account efficacy and toxicity.
MATERIALS AND METHODS
Cell culture and MAbs
Cells of the Burkitt lymphoma-derived B-cell line Raji and the
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Reed-Steinberg cell lines HDLM2, KM/H2 and L428 were
cultured in RPMI-1640 supplemented with 10% heat-inactivated
fetal calf serum (FCS), 2 mM L-glutamine, 100 IU ml-l penicillin
and 100 j gml-' streptomycin, in humidified air with 5% carbon
dioxide at 37°C. Endothelial cells were isolated from human
umbilical vein (HUVECs) and cultured as described above, except
that FCS was replaced with 10% heat-inactivated human AB
serum. The cell lines HepG2 (hepatocyte derived), A431 (epider-
moid vulva carcinoma derived) and its derivative, a B7-1-trans-
fected and -expressing A431, were cultured in Dulbecco's
modified Eagle medium supplemented as described above.
Normal bone marrow (BM) was obtained from patients under-
going cardiac surgery. Specimens were obtained with appropriate
informed consent. Heparinized samples were diluted 1 + 1 with
phosphate-buffered saline (PBS), and mononuclear cells were
isolated by gradient centrifugation on Ficoll-Hypaque.
Murine MAb B7-24 (IgG2a) directed against the human B7-1
antigen was obtained from Innogenetics, Ghent, Belgium (De
Boer et al, 1992). MAbs reactive with CD3, CD14, CD19, CD34,
goat anti-mouse antibodies conjugated to fluorescein isothio-
cyanate (FITC) and phycoerythrin (PE) and streptavidin-PE were
purchased from Becton Dickinson (San Jose, CA, USA).
Figure 1 Lymph node section of a patient with HD. (A) Staining with B7-24,
magnification 150x. (B) Staining with anti-CD30, magnification 1OOx
Preparation of anti-B7-1-saporin IT
Anti-B7-1 IT was prepared as described previously (Vooijs et al,
1996) and consisted ofB7-24 MAb conjugated to the type 1 ribo-
some-inactivatingproteinsaporin. Large-scalesaporinpurification
was performed as described previously (Barbieri et al, 1987). The
MAb andthetoxin wereconjugatedvia adisulphidebondbetween
added sulphydryl (SH) groups.
Briefly, SH groups were introduced separately in the MAb and
in the toxin by 2-iminothiolane treatment. To obtain an optimal
toxin-MAb ratio, theexperimental conditions werechosen sothat,
per toxin or MAb molecule, one or two SH groups, respectively,
would be introduced (1 and 0.6 mM 2-iminothiolane, respectively,
were added in 50 mm sodiumborate buffer, pH 9). To quantify the
amount of toxin conjugated in the resulting IT, a trace of 125I-
labelled saporin was added to the toxin solution. Ellman's reagent
was added to determine the number ofintroduced SH groups and
to protect the SH groups to avoid self-conjugation of toxin or
MAb. The excess of Ellman's reagent was removed by Sephadex
G-25 gel filtration. The modifiedtoxin wasreducedwith 20 mM 3-
mercaptoethanol to free its SH groups and was separated from j-
mercaptoethanol by chromatography on a Sephadex G25 column
and was collected directly onto the unreduced derivatized MAb.
After concentration, the conjugation was allowed to proceed for
16 h at room temperature. The immunotoxin was collected from
this reaction mixture by gel filtration on Sephacryl S-200.
Conjugation and all gel filtrations were performed in phosphate-
buffered saline, pH 7.5. The MAb and toxin content ofthe IT was
estimated by the absorbance at A280 and from the amount of
radioactivity.
Binding activity ofthe anti-B7-1 IT was checked by means ofa
competition experiment with biotin-labelled B7-24 and compared
with the competition with free MAb. Raji cells were incubated
with 5 jg mi' biotin-labelled B7-24 MAb in the presence of
increasing amounts ofIT or free MAb for 20 min at4°C and were
subsequently stained with a phycoerythrin-conjugated strepta-
vidin. Scoring was performed with a FACScan flow cytometer




Figure 2 Flowcytometric analysis of B7-1 expression on cell lines Raji (A),
HDLM2 (B), KM/H2 (C) and L428 (D). Cells were stained with B7-24 followed
by FITC-conjugated goat anti-mouse 1g (shaded peak). As negative control
staining, an isotype-matched mouse Ig was used (clear peak)
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Table 1 Biochemical characterization and activity of anti-B7-1 IT
SH groups Introduced Toxin-MAb ratio Activitya
(ng/ml)b
Saporin MAb
Free saporin - - - 1.8
Anti-B7-1-saporin 1.12 1.79 0.73 3.2
aInhibition ofcell-free protein synthesis after reduction of the disulphide bond.
The concentration is expressed atwhich 50% of the protein synthesis is
inhibited. bAs saporin.
MAb.ba:me
Figure 3 Raji cells were stained with biotin-labelled B7-24 in the presence
of increasing amounts of free MAb or IT to determine the amount of
competition as a measure of binding activity. Cells were incubated for 20 min
at 40C and stained with phycoerythrin-conjugated streptavidin. Cells were
analysed with a flow cytometer. Data are expressed as a percentage of the
mean channel fluorescence intensity (MFI) of the biotin-labelled B7-24 alone
(MFI = 994). *, B7-24; E, anti-B7-1 IT
Protein synthesis inhibition assays
Ribosome inactivation activity offree and conjugated saporin was
tested in a reticulocyte lysate system, as described previously
(Parente et al, 1993).
The cytotoxic effectofthe IT on cells was assessedbymeasuring
their capacity to inhibit protein synthesis in a concentration-depen-
dent way. Cells were seeded in 96-well round-bottom plates and
incubated with anti-B7-1 IT or a mixture ofMAb + saporin for72 h
in concentrations ranging from 103 M to 10-8 M referring to the
saporin moiety. Thereafter [3H]leucine (1 gCi) was added to each
well, followed by an ovemight incubation, resulting in a total
incubation time in the presence ofIT of88 h. This incubation time
resulted inthe optimal cytotoxic effect, as determined bymeasuring
[3H]leucine incorporation at various times after cell exposure to
the IT. Results wereexpressed as percentage [3H]leucine incorpora-
tion with regard to mock-treated cells. Background values of
[3H]leucine incorporation wereobtainedby incubation with 0.1 mM
cycloheximide. TheIC50 value is theconcentration ofIT needed for
a 50% inhibition ofleucine incorporation.
Immunohistochemistry
Immunohistochemistry was performed on frozen tissue sections
of 6-8 gm thickness from lymphoid and non-lymphoid organs.




Figure 4 Cytotoxicity of anti-137-1 IT to different B37-1 -expressing cell lines:
Raji (A), HDLM2 (B), KM/H2 (C) and L428 (D). Cells were incubated with
different concentrations of IT or MAb + free saporin as control for 72 h and
additionally (16 h) with [3HJleucine. Inhibition of protein synthesis is
expressed as percentage of [3H]Ieucine incorporation by untreated cells.
Concentrations refer to the amount of saporin in the IT used.E, Anti-137-1
+ saponn; @, anti-137-1 IT. Data represent mean of three independent
experiments. Standard deviations were less than 10%
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incubated with MAb at 10gg ml-' (60 min, room temperature).
Thereafter, sections were incubated with biotinylated horse anti-
mouse immunoglobulin and streptavidin conjugated to horseradish
peroxidase (Vector, WI, USA). Colourdevelopment was done with
3'3-diaminobenzidine tetrahydrochloride and hydrogen peroxide
as substrates. Sections were counterstained with haematoxylin.















Cells (0.1-0.2 x 106 per sample) were incubated for 15 min at 4°C
with, firstly, MAb (10 jg ml-'). After washing twice in culture
medium, the cells were further incubated for 15 min at 4°C with
goat anti-mouse antibodies conjugated to fluorescein isothio-
cyanate (FITC) or phycoerythrin (PE). The cells were washed
twice and finally suspended in PBS supplemented with 1% bovine
serum albumin (BSA) and 0.1% sodium azide and analysed with a
FACScan flow cytometer.
Toxicity to haematopoietic progenitor cells (HPC)
Bone marrow mononuclear cells were resuspended in RPMI1640
containing 10% AB serum, 2 mmL-glutamine, 100 IU ml-' penicillin
and 100jig ml-' streptomycin with or without 10- M anti-B7-1 IT or
MAb + saporin separately. For the enumeration of colony-forming
unit granulocyte-macrophage (CFU-GM) colonies, 100 units ml-'
granulocyte-macrophage colony-stimulating factor (GM-CSF) and
10 units ml-1 interleukin 3 (1L-3) were added; for burst-forming
unit eryftroid (BFU-E), 3 units ml-1 erythropoietin (Epo); and for
colony-forming unit granulocyte-erythroid-macrophage-megakary-
ocyte (CFU-GEMM), 10 units ml-' IL-3 and 3 units ml-' Epo.
Methylcellulose was added to a final concentration of0.9%. Finally,
the cells (2 x 105) wereplated out in 3-cm Petri dishes and incubated
at 37°C and 5% carbon dioxide. After 14 days, colonies of>20 cells
were counted.
Clonogenic assay
A modification of the clonogenic assay according to Bast was
performed (Bast et al, 1985; Haagen et al, 1995; Post et al, 1995).
Briefly, a series of 12 serial fivefold dilutions (six aliquots of
100 jl perdilution) wereprepared from cell lines Raji and KM/H2
(starting concentrations 106, 105, 104 and 103 cells ml-') in 96-well
flat-bottom plates. Subsequently, 2 x 105 irradiated peripheral
blood mononuclear cells (PBMCs), per well were added as
feeders. Cells were incubated with the mixture of MAb + saporin
or with anti-B7-1 IT at a concentration of 10-8 M (referring to the
saporin moiety) in a total volume of200 jil at 370C and 5% carbon
dioxide. After 14 days, the plates were microscopically scored for
colony outgrowth. The number of clonogenic units (CU) was
calculated using a Spearman estimate (Johnson and Brown, 1961).
The logarithmic (log) kill of IT can be determined by comparing
the CU oftreated and untreated cells.
RESULTS
Immunohistochemistry
To evaluate the potential cross-reactivity ofanti-B7-1 IT, immuno-
histochemistry was performed with anti-B7-1 MAb on samples of
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Figure 5 (A) Specificity of anti-B7-1 IT for B7-1 antigen-expressing cells.
B7-1-negative cell line A431 and a B7-1-transfected and -expressing A431
derivative were incubated with different concentrations of IT for 72 h and
pulse labelled with [3H]leucine. Inhibition of protein synthesis is expressed as
percentage of [3H]leucine incorporation by untreated cells. Concentrations
refer to the amount of saporin in the IT used. *, A431; *, B7-1-transfected
A431. (B) Inhibition of anti-B7-1 IT cytotoxicity by free anti-B7-1 MAb. Raji
cells were incubated with 1Q8 M anti-B7-1 IT in the presence of increasing
amounts of free anti-B7-1 MAb or an isotype-matched irrelevant MAb. The
cells were pulse labelled with [3H]leucine. Inhibition of protein synthesis is
expressed as percentage of [3H]leucine incorporation by untreated cells.
*, Anti-B7-1 MAb; *, irrelevant MAb
non-lymphoid tissues (adrenal gland, stomach, duodenum, thyroid
gland, liver, lung, kidney, brain and skin).
Reactivity in the thymus was restricted to stromal cells, mainly
in the medullary area and in the cortex. In spleen, tonsil and lymph
node, most of the reactivity was found on macrophages and
dendritic cells in the T-cell area and sinuses. B-cell reactivity was
limited to the larger cells in the germinal centre; plasma cells were
negative for B7-1. Reactivity in non-lymphoid tissues was limited
to a weak staining of some stromal cells [macrophage (-like
cells)s] or individual (B-) lymphocytes. Langerhans cells in the
skin were negative. No reactivity was seen with other tissue
components, such as endothelium, epithelium, connective tissue,
muscle and neural cells (data not shown).
Reactivity ofB7-24 on lymph node sections often patients with
HD was compared with the reactivity of a CD30 MAb. A typical
staining pattern ofB7-24 andCD30 on HD lymph node is depicted
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Table 2 Influence of anti-B7-1 IT on the clonogenic growth of B7-1+ cells
Treatment Raji KM/H2
Clonogenic Log kill Clonogenic Log kill
units units
0.9x105 - 1.0X106 -
Anti-B7-1 +saporin 1.0x 105 0 1.2x 106 0
Anti-B7-1 IT(10-8M) 1.0x 102 3 0.6x 102 4.3
Clonogenic assay is performed as described in Materials and methods.
Briefly, Raji and KM/H2 cells were cultured in the presence of culture medium
only (-), with 104 M free B7-24 and free saporin (anti-B7-1 + saporin) or with
a single dose of 10 8 M anti-B7-1 IT. Clonogenic units were determined after
2 weeks of culture and calculated using a Spearman estimate.
in Figure 1, showing that both B7-1 and CD30 have a similar
strong expression on H/R-S cells.
Reactivity of anti-B7-1 MAb with haematopoietic cells
and cell lines
B7-1 expression on mononuclear cells from peripheral blood and
bone marrow and polymorphonuclear granulocytes from periph-
eral blood was determined by incubation of the cells with B7-24.
In peripheral blood, B7-1 expression was found on about 5% ofthe
monocytes (CD14+), but not on B-cells (CD19+), T-cells (CD3+) or
granulocytes (data not shown).
After activation with interferon-y, about 80% of the monocytes
became positive with an expression level similar to EBV-B cells
(data not shown). Double fluorescence of B7-24 and anti-CD34
MAb showed no expression of B7-1 on CD34+ cells from bone
marrow on three independent samples (data not shown).
Expression of B7-1 using B7-24 MAb was also determined on
several cell lines. Results are shown in Figure 2. B7-1 was
expressed on cell lines Raji and R-S cell lines KM/H2 and L428 at
a similar level; R-S cell line HDLM2 had a slightly lower expres-
sion. The cell lines A431 and HepG2, and HUVECs did not show
expression ofB7-1.
Characterization and cytotoxicity of anti-B7-1 IT
The biochemical characterization of anti-B7-1 IT is shown in
Table 1. The conjugation ratio is near the desired optimum of
1 mol of toxin per mol of MAb. Saporin activity is retained suffi-
ciently, as determined on reticulocyte lysate and compared with
free saporin.
Binding activity of the anti-B7-1 IT to the target cell was
compared with the binding of the native MAb. Raji cells were
stained with biotinylated B7-24 in the presence of increasing
concentrations of native MAb or IT and stained with second-step
streptavidin-PE. Results are shown in Figure 3. The binding of
anti-B7-1 IT was almost similar to the binding ofB7-24.
The specific activity of the IT was determined by the treatment
of different B7-1-expressing cell lines. Results are shown in
Figure 4.
Anti-B7-1 IT appeared cytotoxic for Raji cells and the R-S cell
lines HDLM2, KM/H2 and L428. No cytotoxic effect of free
saporin, MAb or the mixture ofthe two was seen with the concen-
tration range used. No cytotoxicity was found on the B7-l-nega-
tive cell lines A431, HepG2 or HUVECs (data not shown).
Table 3 Influence of anti-B7-1 IT treatment on haematopoietic progenitor
cells from healthy human bone marrow
CFU-GEMM (%) CFU-GM (%) BFU-E (%)
100 100 100
(27-35) (145-425) (204-386)
Anti-B7-1 + saporin 85 ± 4 90 ± 10 74 ± 5
Anti-B7-1 IT 90 ± 5 94± 12 88± 10
Anti-CD71 IT 0 0 0
Bone marrow mononuclear cells (n = 3) were incubated with either culture
medium (-), free MAb with free saporin (anti-B7-1 + saporin) or anti-B7-1 IT.
Anti-CD71 IT, targeted to the transferrin receptor, was used as positive
control. CFU-GEMM, CFU-GM and BFU-E were determined as decribed in
Materials and methods. Because of the wide range of colonies found in the
different samples, colony numbers are expressed as a percentage of the
number of colonies found with culture medium (range of number of colonies
is shown between brackets).
The specificity ofthe anti-B7-1 IT was proven by incubation of
a B7-1-transfected A431. A431 normally lacks expression ofB7-1
and is not affected by the IT, however a B7-1-expressing transfec-
tant of A431 was effectively inhibited in its protein synthesis by
anti-B7-1 IT (Figure SA). The cytotoxicity of anti-B7-1 IT was
also inhibited by the addition offree B7-24, but notby the addition
of an isotype-matched control MAb (Figure 5B).
Clonogenic assay
To examine whether treatment of B7-1-expressing cells with anti-
B7-1 IT affects clonogenicity of these cells, and to get a more
quantitative measurement, a clonogenic assay was performed with
Raji cells and KM/H2 cells, which both show good clonogenic
growth in vitro. With untreated cells, about 105 clonogenic units
were scored with Raji cells and 106 clonogenic units with KM/H2.
As shown inTable 2, treatment with anti-B7-1 ITresulted in a 3-
log kill in the case ofRaji and a more than 4-log kill in the case of
KM/H2 cells, whereas incubation with anti B7-1 and saporin sepa-
rately had no effect on clonogenic growth ofeither cell line.
Effect on haematopoietic progenitor cells
The effect of treatment on bone marrow with anti-B7-1 IT was
studied by incubating bone marrow mononuclear cells with IT
(10O8-M) and subsequently determining CFU-GEMM, CFU-GM
and BFU-E. Only a slight inhibition of colony growth of normal
BM HPC (Table 3) was seen with anti-B7-1 IT. This inhibition was
not significantly different from the inhibition found with anti-B7-1
and saporin when added separately. An anti-transferrin receptor
MAb-saporin IT (anti-CD71 IT) was used as positive control
and resulted in the complete abrogation of haematopoietic
progenitor cells.
DISCUSSION
The mouse IgG2a MAb against B7-1 (B7-24) used in this study
appeared to have strong reactivity with R-S cell lines and with
H/R-S cells in immunohistochemistry. B7-1 expression on H/R-S
cells was more or less similar to CD30 expression, confirming
previously published data (Nozawa et al, 1993; Gruss et al, 1994;
Munro et al, 1994). In addition to H/R-S cells, reactivity in normal
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tissue was found, including dendritic cells (DC), activated
macrophages and activated B-cells but not with resting B-cells or
plasma cells, consistent with previously published data (Freeman
et al, 1989; Guinan et al, 1994). In peripheral blood, no reactivity
was found with lymphocytes, granulocytes or the large majority of
monocytes. Not reported before is the absolute absence of expres-
sion of B7-1 on CD34+ cells, representing the haematopoietic
progenitor cells. Furthermore, in the screening of a large number
of normal tissues by immunohistochemistry, no evidence was
found for reactivity of anti-B7-1 MAb with endothelium,
epithelium, connective tissue, muscle or neural cells.
The newly constructed B7-1 immunotoxin with saporin as toxin
moiety appeared to effectively inhibit protein synthesis in the B7-
1-expressing B cell line Raji and the R-S cell lines HDLM2,
KM/H2 and L428, but not in B7-1-negative cell lines. Moreover,
specificity was demonstrated with a B7-1-transfected epithelial
cell line, whose parental line lacks B7-1. Maximum level of
inhibition was reached at an IT concentration of 10-10-10-9 M.
However, this inhibition seems not to be complete. This could be
because of either complete inhibition of protein synthesis in a
percentage of cells or because of an incomplete inhibition in all
cells. To investigate in more detail and the effect of inhibition on
cell growth, clonogenic cell assays were performed, which have
been shown to be more sensitive and to provide a quantitative
measurement of cytotoxic potency (Post et al, 1995). In such a
clonogenic cell assay with the B cell line Raji and R-S cell line
KM/H2 a 3-log kill and a4-log kill, respectively, was found with a
single dose of 10-8 M B7-1 IT; a small population ofcells survived.
Therefore, it is more likely that protein synthesis is inhibited
completely in a large percentage of cells, but that some cells are
not affected under these conditions. The cytotoxic potency ofthis
B7-1 IT shows that B7-1 can be intemalized upon binding of the
MAb. In line with ourdata on absent expression ofB7-1 on CD34+
cells from bone marrow, B7-1 IT did not affect the formation of
CFU-GEMM, CFU-GM and BFU-E from HPC.
In vitro, the B7-1 ITshows an efficacy againstR-S cell lines that
is similar tothatdescribed forCD30 IT (Engert et al, 1990; Tazzari
et al, 1992). CD30 ITs have been further tested in a SCID mouse
model (Engert etal, 1990; Pasqualucci et al, 1995) and comparison
of B7-1 IT and CD30 IT in such a model with R-S
cell lines would reveal any difference in efficacy in vivo. Of
importance when considering in vivo use in humans may be that
soluble CD30 is described in patients with advanced HD
(Josimovic et al, 1989; Pizzolo etal, 1990; Gause et al, 1991). This
soluble form may intercept the IT before it reaches the tumour site
and thereby negatively influence the therapeutic efficacy. Data on
the presence of soluble B7-1 are still lacking. If IT is both effica-
cious in vitro and in vivo in the SCID mouse model, differences in
toxicity will be important when choosing between these two IT. In
addition, a B7-1 IT could be useful in combination with CD30
IT to eliminate variants with or without a low expression of one
ofthe antigens.
Based on the literature, our immunohistochemistry data and data
from FACS analysis, one can expect the following side-effects from
systemic B7-1 IT treatment. B7-1 is constitutively expressed on
lymphoid dendritic cells of mice and humans (Young et al, 1992;
Vandenberghe et al, 1993; Caux et al, 1994; Larsen et al, 1994;
Zhiou et al, 1995) and on activated B-cells and mono-
cytes/macrophages, i.e. on all antigen-presenting cells (APC)
(Freeman et al, 1989; Guinan et al, 1994). These cells would, prob-
ably, all be killed by a B7-1 IT as has been shown by us for activated
B-cells. It can be expected that systemic administration of B7-1 IT
will result in transient elimination ofactivated (lymphoid) dendritic
cells, as these cells will rapidly be replaced by circulating non-
lymphoid dendritic cells, whichhavebeen shown nottoexpress B7-
1 (McLellan et al, 1995), andeventually alsoby CD34+ HPC, which
havealsobeenfoundtobenegativeforB7-1. The samerepopulation
applies to activated monocytes and macrophages. Some
macrophages, such as alveolar macrophages, will be spared as they
seem to be B7-1 negative (Chelen et al, 1995). It is still a matter of
debate whether Langerhans cells (LC) express B7-1 (Symington et
al, 1993; Vandenberghe et al, 1993). In this study, no reactivity of
Langerhans cells in situ was found. Primary responses may there-
fore be only slightly affected but will still be possible after treat-
ment. Activated B-cells will be rapidly replaced by resting B-cells,
andongoing antibody production willnotbeaffectedasplasmacells
lackB7-1. AnotherimportantpointisthatactivatedT-cells andcyto-
toxic T-lymphocytes (CTLs) are independent of B7 stimulation,
hence these responses will notbe affectedby B7-1 IT (Azuma et al,
1992; Azuma et al, 1993).
We postulate that transient elimination of activated APC will
not seriously affect primary immune responses and the defence
against micro-organisms. On the other hand, such elimination
of APC may have a favourable effect, as responses to mouse
antibodies (HAMA) and toxins (HATA) may be prevented.
Particularly in patients with solid tumours (Hertler et al, 1988; Pai
et al, 1991) and also inpatients with HD (Falini etal, 1992b; Falini
et al, 1995), these responses often occur after 2-3 weeks,
precluding repeated administration ofantibodies. IfB7-1 IT really
prevents HAMA and HATA responses without affecting ongoing
immune responses, aB7-1 IT may be an appropriate adjunctto any
MAb or IT treatment.
We conclude that furtherexploration ofthe efficacy andtoxicity
of B7-1 IT in comparison to CD30 IT for the treatment of HD
seems to be warranted.
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